Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current treatment for chronic hepatitis C.

G L Davis1

  • 1Section of Hepatobiliary Diseases, Department of Medicine, University of Florida College of Medicine, Gainesville, FL, USA.

Reviews in Gastroenterological Disorders
|July 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018-2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).

The Journal of hospital infection·2022
Same author

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

Journal of viral hepatitis·2014
Same author

Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Radium content of ultramafic igneous rocks; laboratory investigation.

American journal of science·2010
Same author

Planning the hospital for community service.

Minnesota medicine·2010
Same journal

Prevalence and risk factors of fecal incontinence in community-dwelling men.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea - novel transdermal patch vaccine to prevent travelers' diarrhea.

Reviews in gastroenterological disorders·2010
Same journal

Peptic ulcer bleeding following therapeutic endoscopy: a new indication for intravenous esomeprazole.

Reviews in gastroenterological disorders·2010
Same journal

Diarrhea--cryptosporidial diarrhea in patients with AIDS: impressive results with Rifaximin.

Reviews in gastroenterological disorders·2009
Same journal

Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction.

Reviews in gastroenterological disorders·2009
Same journal

Antimicrobial resistance and eradication strategies for Helicobacter pylori.

Reviews in gastroenterological disorders·2009
See all related articles

Hepatitis C treatment has advanced significantly. Combining interferon with ribavirin improves sustained virologic response rates, with newer pegylated interferon further increasing effectiveness.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Chronic hepatitis C treatment has evolved over the past decade.
  • Early interferon monotherapy yielded limited sustained virologic response (SVR) rates (<10%).
  • Extended interferon courses offered marginal improvements in SVR.

Purpose of the Study:

  • To review the advancements in hepatitis C treatment.
  • To highlight the efficacy of combination therapy.
  • To discuss the impact of novel therapeutic agents.

Main Methods:

  • Review of historical and recent treatment regimens for chronic hepatitis C.
  • Analysis of sustained virologic response rates associated with different therapies.
  • Inclusion of data on interferon, ribavirin, and pegylated interferon combination therapies.

Related Experiment Videos

Main Results:

  • Interferon and ribavirin combination therapy achieved SVR in 30-40% of previously untreated patients.
  • Pegylated interferon, when combined with ribavirin, increased SVR rates to over 50%.
  • Pegylated interferon offers improved administration ease.

Conclusions:

  • Combination therapy with interferon and ribavirin represents a major advance in hepatitis C treatment.
  • Pegylated interferon further enhances treatment efficacy and patient convenience.
  • Current treatment strategies offer significantly improved outcomes for chronic hepatitis C patients.